Search results
Results from the WOW.Com Content Network
Cryoprecipitate should not be used to treat haemophilia, von Willebrand’s disease or deficiencies of Factor XIII or fibronectin except in cases where alternative therapies are unavailable. A typical adult dose is 10 units of whole blood-derived cryoprecipitate, equivalent to a fibrinogen dose of approximately 3−4 g.
The term cryosupernatant (also called cryo-poor plasma, cryoprecipitate depleted, cryoprecipitate reduced plasma) refers to plasma from which the cryoprecipitate has been removed. It is used to treat thrombocytopenic purpura .
Cryoprecipitate or fibrinogen concentrates should be used when fibrinogen is needed. For treatment of hemophilia A , recombinant factor VIII concentrates are available. For treatment of severe hemophilia B , recombinant factor IX concentrates are available.
A blood product is any therapeutic substance prepared from human blood. [1] This includes whole blood; blood components; and plasma derivatives.Blood components include: red blood cell concentrates or suspensions; platelets produced from whole blood or via apheresis;Granulocyte, plasma; and cryoprecipitate.
Whole blood is not commonly used outside of the developing world and military. [2] It is used to make a number of blood products including packed red blood cells, platelet concentrate, cryoprecipitate, and fresh frozen plasma. [1]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Plasma can be further processed to manufacture albumin protein, clotting factor concentrates, cryoprecipitate, fibrinogen concentrate, and immunoglobulins . Red cells, plasma and platelets can also be donated individually via a more complex process called apheresis. Glass used in an antiquated method of blood transfusion.
The most common type of treatment is cryoprecipitate a fibrinogen concentrate used in a drip to increase fibrinogen levels to normal during surgical procedures or after trauma. [11] [2] RiaSTAP, a factor I concentrate, was approved by the U.S. FDA in 2009 for use when the fibrinogen level was below 50 mg/deciliter of plasma. [12]